Literature DB >> 3631906

Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas.

A Macias, E Azavedo, T Hägerström, C Klintenberg, R Pérez, L Skoog.   

Abstract

125I-EGF binding technique was used to demonstrate high affinity receptor binding for epidermal growth factor (EGF-R) in 72 human mammary carcinomas. 27% of the tumors were EGF-R positive and the presence of this receptor was correlated with receptor levels for estradiol, DNA-pattern, proliferative index, thymidine kinase, tumor size, number of lymph node metastases and 6-year relapse probability. Our results confirm previous reports of an inverse relation between the cellular content of EGF-R and ER. In addition, we could associate EGF-R positivity with an aneuploid DNA-pattern and an increased growth rate, as measured by proliferative index. No correlation was found between EGF-R positivity in the primary tumor and presence of axillary lymph node metastasis at the time of operation. The 6-year relapse rate was somewhat higher for patients whose primary tumors were EGF-R positive. Moreover patients who had lymph node metastases at the time of operation and EGF-R positive tumors experienced a significantly lower 6-year disease free survival rate as compared to those who were node negative and had receptor negative tumors. It remains to be shown whether EGF-R alone can be used as an independent prognostic factor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3631906

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer.

Authors:  J L Formento; M Francoual; P Formento; M C Etienne; J L Fischel; M Namer; M Frenay; E François; G Milano
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

2.  Epidermal growth factor receptor in adenocarcinoma of the kidney.

Authors:  K E Ambs; A Takahashi; F Hering; S Costa; P R Huber
Journal:  Urol Res       Date:  1989

Review 3.  Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.

Authors:  S B Noonberg; C C Benz
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

5.  Stearate inhibition of breast cancer cell proliferation. A mechanism involving epidermal growth factor receptor and G-proteins.

Authors:  N S Wickramasinghe; H Jo; J M McDonald; R W Hardy
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

6.  Biotinylated epidermal growth factor: a useful tool for the histochemical analysis of specific binding sites.

Authors:  K Kayser; G Weisse; H J Gabius; T Hintze
Journal:  Histochem J       Date:  1990-08

7.  Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs).

Authors:  E M Hiesiger; R L Hayes; D M Pierz; G N Budzilovich
Journal:  J Neurooncol       Date:  1993-05       Impact factor: 4.130

8.  The prognostic significance of epidermal growth factor receptor expression in breast cancer.

Authors:  M Noguchi; Y Mizukami; K Kinoshita; M Earashi; M Thomas; I Miyazaki
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

9.  The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.

Authors:  S B Fox; K Smith; J Hollyer; M Greenall; D Hastrich; A L Harris
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

10.  Prognostic value of epidermal growth factor receptor in node-positive breast cancer.

Authors:  M Grimaux; S Romain; Y Remvikos; P M Martin; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.